肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：TRAIL-R2激动性抗体DS-8273a靶向MDSC治疗肿瘤患者

2017-07-01 MedSci MedSci原创

MDSCTRAIL-R2肿瘤患者
关注

髓源性抑制细胞（MDSC）是肿瘤中存在免疫抑制的主要原因之一。已有基础实验证明MDSC对TRAIL受体2（TRAIL-R2）激动剂敏感。CANCER RES近期发表了一篇文章，研究在临床上靶向TRAIL-R2是否可以选择性清除MDSC

髓源性抑制细胞（MDSC）是肿瘤中存在免疫抑制的主要原因之一。已有基础实验证明MDSC对TRAIL受体2（TRAIL-R2）激动剂敏感。CANCER RES近期发表了一篇文章，研究在临床上靶向TRAIL-R2是否可以选择性清除MDSC。

Ⅰ期临床实验中共纳入16例晚期肿瘤患者。TRAIL-R2激动性抗体（DS-8273a）24mg/kg每3周1次通过静脉注射，直到出现病情进展、不可耐受的毒性反应或不同意继续进行治疗。作者评估了该抗体的安全性并检测外周血和肿瘤组织中髓系细胞及淋巴细胞比例。研究表明该治疗患者耐受性良好，针对该抗体只出现了轻度到中度的不良反应。与健康志愿者外周血MDSC数目相比，大部分接受DS-8273a治疗的患者外周血MDSC数目下降。几例患者在42天MDSC反弹到治疗前水平。同时，DS-8273a并不会影响中性粒细胞、单核细胞以及其他髓系细胞和淋巴细胞数量。MDSC数目下降与无进展生存时间呈负相关。可以提供治疗前及治疗活检标本的患者检测了肿瘤组织，其中50%的患者在接受DS8273a治疗后出现MDSC下降。

文章最后得出结论，靶向TRAIL-R2可以降低MDSC细胞数目，同时不影响成熟粒细胞及淋巴细胞。本研究中得到的数据支持该抗体在肿瘤免疫治疗中的应用。

原始出处：
George A.Dominguez,Thoams Condamine,et al.Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody.CLIN CANCER RES.June 2017 doi:10.1158/1078-0432.CCR-16-1784

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1842788, encodeId=7bd11842e88d2, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Mon Sep 25 09:27:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656824, encodeId=c85e165682428, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Dec 04 06:27:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935409, encodeId=79301935409cc, content=<a href='/topic/show?id=efb91e73053' target=_blank style='color:#2F92EE;'>#TRAIL-R2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17730, encryptionId=efb91e73053, topicName=TRAIL-R2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Jul 27 02:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647756, encodeId=d0f7164e756d5, content=<a href='/topic/show?id=bc4d1142602' target=_blank style='color:#2F92EE;'>#MDSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11426, encryptionId=bc4d1142602, topicName=MDSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057d23479763, createdName=hxj0125, createdTime=Wed Mar 14 10:27:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424186, encodeId=f63a1424186ca, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488607, encodeId=b691148860ef2, content=<a href='/topic/show?id=7f111e72957' target=_blank style='color:#2F92EE;'>#TRAIL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17729, encryptionId=7f111e72957, topicName=TRAIL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8aa8453364, createdName=zhaohui6734, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218083, encodeId=3a422180833c, content=感谢分享！继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Mon Jul 03 09:45:48 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218022, encodeId=417621802206, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:16 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217579, encodeId=74c521e57955, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:30:08 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-09-25 d830372

    #MDS#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1842788, encodeId=7bd11842e88d2, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Mon Sep 25 09:27:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656824, encodeId=c85e165682428, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Dec 04 06:27:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935409, encodeId=79301935409cc, content=<a href='/topic/show?id=efb91e73053' target=_blank style='color:#2F92EE;'>#TRAIL-R2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17730, encryptionId=efb91e73053, topicName=TRAIL-R2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Jul 27 02:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647756, encodeId=d0f7164e756d5, content=<a href='/topic/show?id=bc4d1142602' target=_blank style='color:#2F92EE;'>#MDSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11426, encryptionId=bc4d1142602, topicName=MDSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057d23479763, createdName=hxj0125, createdTime=Wed Mar 14 10:27:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424186, encodeId=f63a1424186ca, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488607, encodeId=b691148860ef2, content=<a href='/topic/show?id=7f111e72957' target=_blank style='color:#2F92EE;'>#TRAIL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17729, encryptionId=7f111e72957, topicName=TRAIL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8aa8453364, createdName=zhaohui6734, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218083, encodeId=3a422180833c, content=感谢分享！继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Mon Jul 03 09:45:48 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218022, encodeId=417621802206, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:16 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217579, encodeId=74c521e57955, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:30:08 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-12-04 bsmagic9140

    #TRA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1842788, encodeId=7bd11842e88d2, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Mon Sep 25 09:27:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656824, encodeId=c85e165682428, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Dec 04 06:27:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935409, encodeId=79301935409cc, content=<a href='/topic/show?id=efb91e73053' target=_blank style='color:#2F92EE;'>#TRAIL-R2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17730, encryptionId=efb91e73053, topicName=TRAIL-R2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Jul 27 02:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647756, encodeId=d0f7164e756d5, content=<a href='/topic/show?id=bc4d1142602' target=_blank style='color:#2F92EE;'>#MDSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11426, encryptionId=bc4d1142602, topicName=MDSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057d23479763, createdName=hxj0125, createdTime=Wed Mar 14 10:27:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424186, encodeId=f63a1424186ca, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488607, encodeId=b691148860ef2, content=<a href='/topic/show?id=7f111e72957' target=_blank style='color:#2F92EE;'>#TRAIL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17729, encryptionId=7f111e72957, topicName=TRAIL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8aa8453364, createdName=zhaohui6734, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218083, encodeId=3a422180833c, content=感谢分享！继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Mon Jul 03 09:45:48 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218022, encodeId=417621802206, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:16 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217579, encodeId=74c521e57955, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:30:08 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-27 12498484m46(暂无昵称)

    #TRAIL-R2#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1842788, encodeId=7bd11842e88d2, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Mon Sep 25 09:27:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656824, encodeId=c85e165682428, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Dec 04 06:27:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935409, encodeId=79301935409cc, content=<a href='/topic/show?id=efb91e73053' target=_blank style='color:#2F92EE;'>#TRAIL-R2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17730, encryptionId=efb91e73053, topicName=TRAIL-R2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Jul 27 02:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647756, encodeId=d0f7164e756d5, content=<a href='/topic/show?id=bc4d1142602' target=_blank style='color:#2F92EE;'>#MDSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11426, encryptionId=bc4d1142602, topicName=MDSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057d23479763, createdName=hxj0125, createdTime=Wed Mar 14 10:27:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424186, encodeId=f63a1424186ca, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488607, encodeId=b691148860ef2, content=<a href='/topic/show?id=7f111e72957' target=_blank style='color:#2F92EE;'>#TRAIL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17729, encryptionId=7f111e72957, topicName=TRAIL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8aa8453364, createdName=zhaohui6734, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218083, encodeId=3a422180833c, content=感谢分享！继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Mon Jul 03 09:45:48 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218022, encodeId=417621802206, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:16 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217579, encodeId=74c521e57955, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:30:08 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2018-03-14 hxj0125

    #MDSC#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1842788, encodeId=7bd11842e88d2, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Mon Sep 25 09:27:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656824, encodeId=c85e165682428, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Dec 04 06:27:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935409, encodeId=79301935409cc, content=<a href='/topic/show?id=efb91e73053' target=_blank style='color:#2F92EE;'>#TRAIL-R2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17730, encryptionId=efb91e73053, topicName=TRAIL-R2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Jul 27 02:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647756, encodeId=d0f7164e756d5, content=<a href='/topic/show?id=bc4d1142602' target=_blank style='color:#2F92EE;'>#MDSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11426, encryptionId=bc4d1142602, topicName=MDSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057d23479763, createdName=hxj0125, createdTime=Wed Mar 14 10:27:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424186, encodeId=f63a1424186ca, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488607, encodeId=b691148860ef2, content=<a href='/topic/show?id=7f111e72957' target=_blank style='color:#2F92EE;'>#TRAIL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17729, encryptionId=7f111e72957, topicName=TRAIL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8aa8453364, createdName=zhaohui6734, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218083, encodeId=3a422180833c, content=感谢分享！继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Mon Jul 03 09:45:48 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218022, encodeId=417621802206, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:16 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217579, encodeId=74c521e57955, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:30:08 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-03 lanyan20020087

    #肿瘤患者#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1842788, encodeId=7bd11842e88d2, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Mon Sep 25 09:27:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656824, encodeId=c85e165682428, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Dec 04 06:27:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935409, encodeId=79301935409cc, content=<a href='/topic/show?id=efb91e73053' target=_blank style='color:#2F92EE;'>#TRAIL-R2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17730, encryptionId=efb91e73053, topicName=TRAIL-R2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Jul 27 02:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647756, encodeId=d0f7164e756d5, content=<a href='/topic/show?id=bc4d1142602' target=_blank style='color:#2F92EE;'>#MDSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11426, encryptionId=bc4d1142602, topicName=MDSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057d23479763, createdName=hxj0125, createdTime=Wed Mar 14 10:27:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424186, encodeId=f63a1424186ca, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488607, encodeId=b691148860ef2, content=<a href='/topic/show?id=7f111e72957' target=_blank style='color:#2F92EE;'>#TRAIL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17729, encryptionId=7f111e72957, topicName=TRAIL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8aa8453364, createdName=zhaohui6734, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218083, encodeId=3a422180833c, content=感谢分享！继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Mon Jul 03 09:45:48 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218022, encodeId=417621802206, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:16 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217579, encodeId=74c521e57955, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:30:08 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-03 zhaohui6734

    #TRAIL#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1842788, encodeId=7bd11842e88d2, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Mon Sep 25 09:27:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656824, encodeId=c85e165682428, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Dec 04 06:27:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935409, encodeId=79301935409cc, content=<a href='/topic/show?id=efb91e73053' target=_blank style='color:#2F92EE;'>#TRAIL-R2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17730, encryptionId=efb91e73053, topicName=TRAIL-R2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Jul 27 02:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647756, encodeId=d0f7164e756d5, content=<a href='/topic/show?id=bc4d1142602' target=_blank style='color:#2F92EE;'>#MDSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11426, encryptionId=bc4d1142602, topicName=MDSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057d23479763, createdName=hxj0125, createdTime=Wed Mar 14 10:27:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424186, encodeId=f63a1424186ca, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488607, encodeId=b691148860ef2, content=<a href='/topic/show?id=7f111e72957' target=_blank style='color:#2F92EE;'>#TRAIL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17729, encryptionId=7f111e72957, topicName=TRAIL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8aa8453364, createdName=zhaohui6734, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218083, encodeId=3a422180833c, content=感谢分享！继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Mon Jul 03 09:45:48 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218022, encodeId=417621802206, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:16 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217579, encodeId=74c521e57955, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:30:08 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-03 明天会更好！

    感谢分享！继续关注！

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1842788, encodeId=7bd11842e88d2, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Mon Sep 25 09:27:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656824, encodeId=c85e165682428, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Dec 04 06:27:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935409, encodeId=79301935409cc, content=<a href='/topic/show?id=efb91e73053' target=_blank style='color:#2F92EE;'>#TRAIL-R2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17730, encryptionId=efb91e73053, topicName=TRAIL-R2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Jul 27 02:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647756, encodeId=d0f7164e756d5, content=<a href='/topic/show?id=bc4d1142602' target=_blank style='color:#2F92EE;'>#MDSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11426, encryptionId=bc4d1142602, topicName=MDSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057d23479763, createdName=hxj0125, createdTime=Wed Mar 14 10:27:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424186, encodeId=f63a1424186ca, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488607, encodeId=b691148860ef2, content=<a href='/topic/show?id=7f111e72957' target=_blank style='color:#2F92EE;'>#TRAIL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17729, encryptionId=7f111e72957, topicName=TRAIL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8aa8453364, createdName=zhaohui6734, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218083, encodeId=3a422180833c, content=感谢分享！继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Mon Jul 03 09:45:48 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218022, encodeId=417621802206, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:16 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217579, encodeId=74c521e57955, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:30:08 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-03 ylzr123

    好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1842788, encodeId=7bd11842e88d2, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Mon Sep 25 09:27:00 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656824, encodeId=c85e165682428, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Dec 04 06:27:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935409, encodeId=79301935409cc, content=<a href='/topic/show?id=efb91e73053' target=_blank style='color:#2F92EE;'>#TRAIL-R2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17730, encryptionId=efb91e73053, topicName=TRAIL-R2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu Jul 27 02:27:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647756, encodeId=d0f7164e756d5, content=<a href='/topic/show?id=bc4d1142602' target=_blank style='color:#2F92EE;'>#MDSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11426, encryptionId=bc4d1142602, topicName=MDSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=057d23479763, createdName=hxj0125, createdTime=Wed Mar 14 10:27:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424186, encodeId=f63a1424186ca, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488607, encodeId=b691148860ef2, content=<a href='/topic/show?id=7f111e72957' target=_blank style='color:#2F92EE;'>#TRAIL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17729, encryptionId=7f111e72957, topicName=TRAIL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8aa8453364, createdName=zhaohui6734, createdTime=Mon Jul 03 10:27:00 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218083, encodeId=3a422180833c, content=感谢分享！继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Mon Jul 03 09:45:48 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218022, encodeId=417621802206, content=好文，值得点赞！认真学习，应用于实践！谢谢分享给广大同好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Jul 03 07:33:16 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217579, encodeId=74c521e57955, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sun Jul 02 00:30:08 CST 2017, time=2017-07-02, status=1, ipAttribution=)]
    2017-07-02 184****9840

    学习了谢谢分享

    0